DE602004031284D1 - Transposon-system zur gezielten integration - Google Patents

Transposon-system zur gezielten integration

Info

Publication number
DE602004031284D1
DE602004031284D1 DE602004031284T DE602004031284T DE602004031284D1 DE 602004031284 D1 DE602004031284 D1 DE 602004031284D1 DE 602004031284 T DE602004031284 T DE 602004031284T DE 602004031284 T DE602004031284 T DE 602004031284T DE 602004031284 D1 DE602004031284 D1 DE 602004031284D1
Authority
DE
Germany
Prior art keywords
transposase
fragment
derivative
function
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004031284T
Other languages
English (en)
Inventor
Zoltan Ivics
Zsuzsanna Izsvak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of DE602004031284D1 publication Critical patent/DE602004031284D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602004031284T 2003-02-10 2004-02-10 Transposon-system zur gezielten integration Expired - Lifetime DE602004031284D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03002630 2003-02-10
PCT/EP2004/001222 WO2004069995A2 (en) 2003-02-10 2004-02-10 Transposon-based targeting system

Publications (1)

Publication Number Publication Date
DE602004031284D1 true DE602004031284D1 (de) 2011-03-17

Family

ID=32842693

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031284T Expired - Lifetime DE602004031284D1 (de) 2003-02-10 2004-02-10 Transposon-system zur gezielten integration

Country Status (7)

Country Link
US (1) US20060236413A1 (de)
EP (1) EP1594971B1 (de)
JP (1) JP2006517104A (de)
AT (1) ATE497540T1 (de)
DE (1) DE602004031284D1 (de)
DK (1) DK1594971T3 (de)
WO (1) WO2004069995A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040172667A1 (en) 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
US7527966B2 (en) * 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
ATE536419T1 (de) * 2003-02-10 2011-12-15 Max Delbrueck Centrum Transposon basiertes targeting- system
US8071364B2 (en) 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
EP2067402A1 (de) 2007-12-07 2009-06-10 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Transposon-vermittelte Mutagenese in Spermatogoniestammzellen
WO2010036976A2 (en) 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of antibodies
WO2010036978A2 (en) 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of growth hormone
EP2369916A4 (de) 2008-12-01 2013-04-10 Univ Texas Herstellung und verfwendung von spermatogonialen stammzelllinien aus der ratte
WO2010118360A1 (en) 2009-04-09 2010-10-14 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Production of proteins using transposon-based vectors
US9074251B2 (en) * 2011-02-10 2015-07-07 Illumina, Inc. Linking sequence reads using paired code tags
AU2012212148B8 (en) 2011-02-02 2017-07-06 University Of Washington Through Its Center For Commercialization Massively parallel contiguity mapping
EP2740353A1 (de) 2012-12-06 2014-06-11 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Neuartige induzierbare Tiermodelle für Stressverhalten
US9683230B2 (en) 2013-01-09 2017-06-20 Illumina Cambridge Limited Sample preparation on a solid support
AU2013382098B2 (en) 2013-03-13 2019-02-07 Illumina, Inc. Methods and compositions for nucleic acid sequencing
WO2014143383A1 (en) * 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
US10246746B2 (en) 2013-12-20 2019-04-02 Illumina, Inc. Preserving genomic connectivity information in fragmented genomic DNA samples
FR3024464A1 (fr) * 2014-07-30 2016-02-05 Centre Nat Rech Scient Ciblage de vecteurs integratifs non-viraux dans les sequences d'adn nucleolaires chez les eucaryotes
JP6808617B2 (ja) 2014-10-17 2021-01-06 イルミナ ケンブリッジ リミテッド 連続性を維持した転位
US11913015B2 (en) 2017-04-17 2024-02-27 University Of Maryland, College Park Embryonic cell cultures and methods of using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027643A1 (en) * 1993-06-01 1994-12-08 Targeted Genetics Corporation Envelope fusion vectors for use in gene delivery
KR0166606B1 (ko) * 1993-12-07 1999-04-15 가네코 야스조 배선용 바닥 재료
CA2280997C (en) * 1997-03-11 2013-05-28 Perry B. Hackett Dna-based transposon system for the introduction of nucleic acid into dna of a cell
WO1999005295A1 (en) * 1997-07-25 1999-02-04 Thomas Jefferson University Composition and method for targeted integration into cells
WO2001030965A2 (en) * 1999-10-28 2001-05-03 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
IL154059A0 (en) * 2000-07-21 2003-07-31 Syngenta Participations Ag Zinc finger domain recognition code and uses thereof
ES2358994T3 (es) * 2002-07-24 2011-05-17 Manoa Biosciences Inc. Vectores basados en transposones y métodos para la integración de ácidos nucleicos.

Also Published As

Publication number Publication date
JP2006517104A (ja) 2006-07-20
EP1594971B1 (de) 2011-02-02
US20060236413A1 (en) 2006-10-19
DK1594971T3 (da) 2011-05-23
WO2004069995A3 (en) 2004-10-28
EP1594971A2 (de) 2005-11-16
WO2004069995A2 (en) 2004-08-19
ATE497540T1 (de) 2011-02-15

Similar Documents

Publication Publication Date Title
ATE536419T1 (de) Transposon basiertes targeting- system
ATE497540T1 (de) Transposon-system zur gezielten integration
ATE408624T1 (de) Verfahren zur reinigung von fsh
WO2002089738A3 (en) Proteomimetic compounds and methods
WO2005005462A3 (en) Blys antagonists and uses thereof
ATE498016T1 (de) Transposon-system zur gezielten integration
ATE466868T1 (de) Zusammensetzungen und verfahren zur trennung von fusionsproteinen
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
SG162687A1 (en) Caustic stable chromatography ligands
WO2007046006A3 (en) Il-15ralpha sushi domain as a selective and potent enhancer of il-15 action through il-15rbeta/gamma, and hyperagonist (ilralpha sushi-il 15) fusion proteins
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
MX2009005901A (es) Nuevos polipeptidos cristalinos de bacillus thuringiensis, polinucleotidos y composiciones de los mismos.
BRPI0416807A (pt) sistemas de expressão aperfeiçoados com secreção de sistema sec
TW200745159A (en) IL-6 binding proteins
WO2006132739A3 (en) Novel chemical compounds
ATE446314T1 (de) Methode zur reinigung von fsh
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
UY27606A1 (es) Inhibidores de la fosfarasa
WO2007045019A3 (en) Polyoleosins
ATE521626T1 (de) Fusionsprotein zur inhibierung von gebärmutterhalskrebs
IL173506A0 (en) Method for the purification of a non-immunoglobulin protein comprising an immunoglobulin-like (ig-like) domain
WO2006127458A3 (en) Novel chemical compounds
WO2006097336A3 (en) A novel component of the wg/wnt signaling pathway
WO2004090103A8 (en) Identification of novel nogo-receptors and methods related thereto
NO20051938L (no) Promoter til IL-18BP, dens fremstilling og anvendelse